AstraZeneca Launches Health-Tech Business Evinova -- Update
20 November 2023 - 9:41AM
Dow Jones News
By Michael Susin
AstraZeneca said it has launched Evinova, a separate health-tech
business to offer its knowledge of clinical-trial design and study
delivery.
The Anglo-Swedish pharmaceutical giant on Monday said the
business will deliver solutions at scale to trial sponsors,
clinical-research organizations, care teams and patients. This
includes improved data collection and machine-learning algorithms
to support teams designing their studies.
"This will reduce the time and cost of developing new medicines,
bring care closer to home for patients and reduce the burden on
health systems," it said.
The company added that the first major collaborations with
clinical-research organizations Parexel and Fortrea will enable
Evinova's digital-health solutions to be offered to their wide
customer base.
"We believe Evinova's combination of scientific expertise and
track record in developing AI-enabled digital technologies at
scale, provides a real opportunity to fundamentally improve patient
care, drive healthcare transformation and reduce carbon emissions,"
Chief Executive Pascal Soriot said.
The digital-health market is expected to be worth more than $900
billion by 2032, with research and development of digital health
and care delivery with remote patient monitoring making up around
60% of the total market, the company added.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
November 20, 2023 03:26 ET (08:26 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024